본문

  1. Home
406 Results:UU:VOL4 0.140 sec.
RSS 
Multilingual
 Расширенный поиск
 Новый поиск книги прибытия
Selected Print Select Export to Excel
391
Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate
Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate
Allen, M. R., | Elsevier Inc | 2011 ,
392
A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice
A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice
Plotkin, L. I., | Elsevier Inc | 2011 ,
393
The gunmetal mouse reveals Rab geranylgeranyl transferase to be the major molecular target of phosphonocarboxylate analogues of bisphosphonates
The gunmetal mouse reveals Rab geranylgeranyl transferase to be the major molecular target of phosphonocarboxylate analogues of bisphosphonates
Coxon, F. P., | Elsevier Inc | 2011 ,
394
Safety of bisphosphonates
Safety of bisphosphonates
Pazianas, M., | Elsevier Inc | 2011 ,
395
Bisphosphonates in orthopedic applications
Bisphosphonates in orthopedic applications
Wilkinson, J. M., | Elsevier Inc | 2011 ,
396
Bisphosphonates in Paget's disease
Bisphosphonates in Paget's disease
Reid, I. R., | Elsevier Inc | 2011 ,
397
Bisphosphonates for postmenopausal osteoporosis
Bisphosphonates for postmenopausal osteoporosis
Eastell, R., | Elsevier Inc | 2011 ,
398
The kidney and bisphosphonates
The kidney and bisphosphonates
Miller, P. D., | Elsevier Inc | 2011 ,
399
Bisphosphonates in oncology
Bisphosphonates in oncology
Coleman, R. E., | Elsevier Inc | 2011 ,
400
Bisphosphonates in preclinical bone oncology
Bisphosphonates in preclinical bone oncology
Clezardin, P., | Elsevier Inc | 2011 ,
처음이전35363738394041이후마지막